Fundamentals Overview
Jazz Pharmaceuticals plc is near the high of its 52-week range with moderate valuation, trading relatively flat today.
Valuation moderate
Intrinsic value (DCF)
+209.7% upside vs price
Risk (Beta)
0.23 — lower vol
BullzEye Analysis
Our composite tilts Buy on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
DCF +209.7% upside vs price · 3M vs S&P 500: +21.1% · 3M vs Healthcare sector: +27.9%
Pressures (Sell):
Sentiment weakening (1 downgrade)
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: C. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 11, Neutral: 1, Outperform: 6, Overweight: 12.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $617.39; current price is $199.33. That’s a +209.7% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | N/A |
| DCF value (model) | $617.39 (209.7% upside) |
| PEG (TTM) | N/A |
| P/B (TTM) | 2.81 |
| P/S (TTM) | 2.88 |
| P/FCF (TTM) | 9.83 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 1.86 |
| Quick Ratio (TTM) | 1.67 |
| Cash Ratio (TTM) | 0.62 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | -8.35% |
| Gross margin (TTM) | 88.21% |
| Operating margin (TTM) | 5.26% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for JAZZ.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| Piper Sandler | maintain | Overweight | Overweight | 2026-03-19 |
| Morgan Stanley | maintain | Overweight | Overweight | 2026-02-25 |
| RBC Capital | maintain | Outperform | Outperform | 2026-02-25 |
| Wells Fargo | maintain | Overweight | Overweight | 2026-02-25 |
| B of A Securities | maintain | Buy | Buy | 2026-02-25 |
| Needham | maintain | Buy | Buy | 2026-01-12 |
| Truist Securities | maintain | Buy | Buy | 2026-01-12 |
| Piper Sandler | maintain | Overweight | Overweight | 2025-12-10 |
| UBS | downgrade | Buy | Neutral | 2025-11-24 |
| B of A Securities | maintain | Buy | Buy | 2025-11-18 |
| Wells Fargo | maintain | Overweight | Overweight | 2025-11-18 |
| Baird | maintain | Outperform | Outperform | 2025-11-18 |
| Morgan Stanley | maintain | Overweight | Overweight | 2025-11-17 |
| RBC Capital | maintain | Outperform | Outperform | 2025-11-17 |
| RBC Capital | maintain | Outperform | Outperform | 2025-11-06 |
| JP Morgan | maintain | Overweight | Overweight | 2025-10-27 |
| Morgan Stanley | maintain | Overweight | Overweight | 2025-10-20 |
| Morgan Stanley | maintain | Overweight | Overweight | 2025-09-24 |
| Goldman Sachs | maintain | Buy | Buy | 2025-08-29 |
| Needham | maintain | Buy | Buy | 2025-08-28 |
| RBC Capital | maintain | Outperform | Outperform | 2025-08-28 |
| Truist Securities | maintain | Buy | Buy | 2025-08-28 |
| Morgan Stanley | maintain | Overweight | Overweight | 2025-08-28 |
| Needham | maintain | Buy | Buy | 2025-08-20 |
| Morgan Stanley | maintain | Overweight | Overweight | 2025-08-06 |
| Morgan Stanley | maintain | Overweight | Overweight | 2025-07-22 |
| Needham | maintain | Buy | Buy | 2025-06-11 |
| Needham | maintain | Buy | Buy | 2025-06-03 |
| Needham | maintain | Buy | Buy | 2025-05-07 |
| RBC Capital | maintain | Outperform | Outperform | 2025-05-07 |